XML 20 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ / shares in Thousands, $ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Unrestricted cash and cash equivalents $ 339,338 $ 384,984
Restricted cash and cash equivalents 44,315 48,208
Loans, interest and fees receivable, at fair value 2,173,759 1,817,976
Notes payable, at face value $ 1,861,685 $ 1,653,306
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 14,603,563 14,453,415
Common stock, outstanding (in shares) 14,603,563 14,453,415
Series A Preferred Stock [Member]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 400,000 400,000
Preferred stock, shares outstanding (in shares) 400,000 400,000
Preferred stock, liquidation preference $ 40,000 $ 40,000
Series B Preferred Stock [Member]    
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, shares issued (in shares) 3,256,561 3,204,640
Preferred stock, shares outstanding (in shares) 3,256,561 3,204,640
Preferred stock, liquidation preference $ 81,400 $ 81,400
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents 158,000 202,200
Restricted cash and cash equivalents 20,500 27,600
Loans, interest and fees receivable, at fair value 2,128,600 1,735,900
Notes payable, at face value $ 1,795,900 $ 1,586,000